kabutan

Chiome Bioscience Inc.(4583) Summary

4583
TSE Growth
Chiome Bioscience Inc.
110
JPY
+1
(+0.92%)
Dec 12, 3:30 pm JST
0.70
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
109.6
Dec 12, 11:30 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.99
Yield
ー%
Margin Trading Ratio
946.00
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
110 JPY 0.70 USD
Previous Close Dec 11
109 JPY 0.69 USD
High Dec 12, 9:53 am
111 JPY 0.71 USD
Low Dec 12, 1:44 pm
108 JPY 0.69 USD
Volume
558,300
Trading Value
0.06B JPY 0.39M USD
VWAP
109.56 JPY 0.7 USD
Minimum Trading Value
11,000 JPY 70 USD
Market Cap
7.49B JPY 0.05B USD
Number of Trades
129
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
874
1-Year High Dec 13, 2024
9,372
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 5,235,300
Nov 28, 2025 0 5,061,700
Nov 21, 2025 0 5,387,400
Nov 14, 2025 0 5,633,200
Nov 7, 2025 0 5,494,300
Company Profile
Chiome Bioscience Inc. is a drug discovery venture originating from RIKEN. The company specializes in proprietary antibody production technology and generates revenue through licensing.
Sector
Pharmaceuticals
Chiome Bioscience Inc. focuses on developing drug candidates for diseases with high unmet medical needs and supporting antibody drug discovery research, utilizing its core proprietary antibody production technology, the ADLib system. The company's main business area covers upstream processes from basic and exploratory research to preclinical development and early clinical development, with a basic strategy of early out-licensing of development candidate antibodies. In its drug discovery support business, Chiome Bioscience Inc. offers protein expression and purification services as well as antibody production services. The company integrates multiple antibody production technologies to maximize its antibody production capabilities. Chiome Bioscience Inc. has several in-house pipelines, including CBA-1205 and CBA-1535, and is actively promoting new drug discovery projects.